417 related articles for article (PubMed ID: 29920436)
1. Improving small molecule virtual screening strategies for the next generation of therapeutics.
Wingert BM; Camacho CJ
Curr Opin Chem Biol; 2018 Jun; 44():87-92. PubMed ID: 29920436
[TBL] [Abstract][Full Text] [Related]
2. In silico structure-based approaches to discover protein-protein interaction-targeting drugs.
Shin WH; Christoffer CW; Kihara D
Methods; 2017 Dec; 131():22-32. PubMed ID: 28802714
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and screening of small-molecule α-helix mimetic libraries targeting protein-protein interactions.
Moon H; Lim HS
Curr Opin Chem Biol; 2015 Feb; 24():38-47. PubMed ID: 25461722
[TBL] [Abstract][Full Text] [Related]
4. Structure-Based Virtual Screening of Commercially Available Compound Libraries.
Kireev D
Methods Mol Biol; 2016; 1439():65-76. PubMed ID: 27316988
[TBL] [Abstract][Full Text] [Related]
5. Fast Rescoring Protocols to Improve the Performance of Structure-Based Virtual Screening Performed on Protein-Protein Interfaces.
Singh N; Chaput L; Villoutreix BO
J Chem Inf Model; 2020 Aug; 60(8):3910-3934. PubMed ID: 32786511
[TBL] [Abstract][Full Text] [Related]
6. Inhibitors of protein-protein interactions (PPIs): an analysis of scaffold choices and buried surface area.
Ran X; Gestwicki JE
Curr Opin Chem Biol; 2018 Jun; 44():75-86. PubMed ID: 29908451
[TBL] [Abstract][Full Text] [Related]
7. In Silico Target Druggability Assessment: From Structural to Systemic Approaches.
Trosset JY; Cavé C
Methods Mol Biol; 2019; 1953():63-88. PubMed ID: 30912016
[TBL] [Abstract][Full Text] [Related]
8. Structure-based design of small-molecule protein-protein interaction modulators: the story so far.
Falchi F; Caporuscio F; Recanatini M
Future Med Chem; 2014 Mar; 6(3):343-57. PubMed ID: 24575969
[TBL] [Abstract][Full Text] [Related]
9. Benchmark Study Based on 2P2I
Wang Z; Kang Y; Li D; Sun H; Dong X; Yao X; Xu L; Chang S; Li Y; Hou T
J Phys Chem B; 2018 Mar; 122(9):2544-2555. PubMed ID: 29420886
[TBL] [Abstract][Full Text] [Related]
10. Enhancements to the Rosetta Energy Function Enable Improved Identification of Small Molecules that Inhibit Protein-Protein Interactions.
Bazzoli A; Kelow SP; Karanicolas J
PLoS One; 2015; 10(10):e0140359. PubMed ID: 26484863
[TBL] [Abstract][Full Text] [Related]
11. Computational Screening and Design for Compounds that Disrupt Protein-protein Interactions.
Johnson DK; Karanicolas J
Curr Top Med Chem; 2017; 17(23):2703-2714. PubMed ID: 28482793
[TBL] [Abstract][Full Text] [Related]
12. Applications of the NRGsuite and the Molecular Docking Software FlexAID in Computational Drug Discovery and Design.
Morency LP; Gaudreault F; Najmanovich R
Methods Mol Biol; 2018; 1762():367-388. PubMed ID: 29594781
[TBL] [Abstract][Full Text] [Related]
13. Challenges in Discovering Drugs That Target the Protein-Protein Interactions of Disordered Proteins.
Oláh J; Szénási T; Lehotzky A; Norris V; Ovádi J
Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163473
[TBL] [Abstract][Full Text] [Related]
14. Function and structure-based screening of compounds, peptides and proteins to identify drug candidates.
Malik V; Dhanjal JK; Kumari A; Radhakrishnan N; Singh K; Sundar D
Methods; 2017 Dec; 131():10-21. PubMed ID: 28843611
[TBL] [Abstract][Full Text] [Related]
15. Protein Preparation Automatic Protocol for High-Throughput Inverse Virtual Screening: Accelerating the Target Identification by Computational Methods.
De Vita S; Lauro G; Ruggiero D; Terracciano S; Riccio R; Bifulco G
J Chem Inf Model; 2019 Nov; 59(11):4678-4690. PubMed ID: 31593460
[TBL] [Abstract][Full Text] [Related]
16. How to Prepare a Compound Collection Prior to Virtual Screening.
Bologa CG; Ursu O; Oprea TI
Methods Mol Biol; 2019; 1939():119-138. PubMed ID: 30848459
[TBL] [Abstract][Full Text] [Related]
17. Identification of Inhibitors for the Lutheran Blood Group Glycoprotein - Laminin 511/521 Interaction by Molecular Modelling and Simulation Techniques.
Madeleine N; Gardebien F
Curr Comput Aided Drug Des; 2018; 14(3):253-268. PubMed ID: 27439722
[TBL] [Abstract][Full Text] [Related]
18. In silico design of low molecular weight protein-protein interaction inhibitors: Overall concept and recent advances.
Kuenemann MA; Sperandio O; Labbé CM; Lagorce D; Miteva MA; Villoutreix BO
Prog Biophys Mol Biol; 2015 Oct; 119(1):20-32. PubMed ID: 25748546
[TBL] [Abstract][Full Text] [Related]
19. Biophysical and computational fragment-based approaches to targeting protein-protein interactions: applications in structure-guided drug discovery.
Winter A; Higueruelo AP; Marsh M; Sigurdardottir A; Pitt WR; Blundell TL
Q Rev Biophys; 2012 Nov; 45(4):383-426. PubMed ID: 22971516
[TBL] [Abstract][Full Text] [Related]
20. Protein-protein interactions as drug targets.
Skwarczynska M; Ottmann C
Future Med Chem; 2015; 7(16):2195-219. PubMed ID: 26510391
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
